Regentis Biomaterials ^{For Profit}

s of Regentis Biomaterials' hydrogels involve the combination of synthetic materials with natural substances to create a stable and versatile product. The company's flagship product, GelrinC�, is currently undergoing clinical trials for the treatment of articular cartilage lesions. With a focus on tissue regeneration, Regentis Biomaterials aims to provide innovative solutions for orthopedic treatments using resorbable hydrogel implants. The company's achievements include extensive preclinical and safety testing of their hydrogel platform, as well as securing investments from prominent venture capital firms and pharmaceutical companies.